

ACTINIC KERATOSIS

PRODUCTS AFFECTED

- *diclofenac sodium gel 3 % external*
- KLISYRI OINTMENT 1 % EXTERNAL

Details

Criteria	Trial of either topical fluorouracil or topical imiquimod
-----------------	---

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

ANTIDEPRESSANTS

PRODUCTS AFFECTED

- AUVELITY TABLET EXTENDED RELEASE 45-105 MG ORAL
- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

ATYPICAL ANTIPSYCHOTICS

PRODUCTS AFFECTED

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy.
-----------------	---

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

GLUCAGON

PRODUCTS AFFECTED

- GLUCAGEN HYPOKIT SOLUTION
RECONSTITUTED 1 MG INJECTION

Details

Criteria	Trial of one of the following: Gvoke, Baqsimi, or Glucagon
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

INVEGA HAFYERA THERAPY

PRODUCTS AFFECTED

- INVEGA HAFYERA SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML INTRAMUSCULAR
- INVEGA HAFYERA SUSPENSION PREFILLED SYRINGE 1560 MG/5ML INTRAMUSCULAR

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

NAMZARIC

PRODUCTS AFFECTED

- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 21-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG ORAL

Details

Criteria	Trial of generic memantine extended-release
-----------------	---

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

RELISTOR

PRODUCTS AFFECTED

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS (0.6ML SYRINGE)
- RELISTOR SOLUTION 8 MG/0.4ML SUBCUTANEOUS
- RELISTOR TABLET 150 MG ORAL

Details

Criteria	Pending CMS Approval
-----------------	----------------------

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

RYTARY

PRODUCTS AFFECTED

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	Trial of one generic carbidopa/levodopa containing formulation
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

STATINS

PRODUCTS AFFECTED

- LIVALO TABLET 1 MG ORAL
- LIVALO TABLET 2 MG ORAL
- LIVALO TABLET 4 MG ORAL

Details

Criteria	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

ZONISADE SUSPENSION

PRODUCTS AFFECTED

- ZONISADE SUSPENSION 100 MG/5ML ORAL

Details

Criteria	Trial of generic zonisamide capsule. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

Formulary ID: 00024469 & 00024470, Ver.6

Last Updated: 10/02/2023

Effective Date: 01/01/2024

Index of Drugs

INDEX \e " " \c "2" \h "A" \z "1033"